Charles River Laboratories Intl (CRL) 73.61 $CRL
Jim Cramer's 'Mad Money' Recap: Get Ready to Profit on Europe-Induced Weakness
at The Street - Wed Feb 11, 7:14PM CST
Lots of investors are worried about Europe, Cramer says, but you don't have to be.
KMI: 41.97 (+0.21), ACHC: 63.20 (-0.45), FLEX: 12.05 (-0.09), GE: 25.15 (+0.26), BBT: 38.28 (-0.04), AWAY: 29.68 (+0.11), XOM: 93.37 (+1.00), KEY: 14.11 (-0.08), INTC: 34.36 (+0.23), AFFX: 11.45 (+0.02), TWX: 83.87 (+0.56), PEP: 99.13 (-1.14), AEP: 57.83 (-0.15), ETP: 60.17 (+0.96), CMG: 674.89 (+4.60), QLYS: 47.95 (+1.46), GOOGL: 551.16 (+5.15), MSFT: 43.87 (+0.78), HSIC: 143.18 (+0.72), AAPL: 127.08 (+0.62), REGN: 402.40 (+0.66), CSCO: 29.43 (-0.03), CY: 14.76 (+0.01), SWKS: 81.85 (-0.57), PWR: 28.76 (-0.10), FB: 75.74 (-0.49), PFE: 34.64 (-0.23), HAL: 44.19 (+1.42), AMGN: 153.48 (+0.30), BAC: 16.61 (-0.06), BMY: 60.04 (+0.56), BA: 149.73 (+1.64), HPQ: 38.56 (+0.19), RAD: 8.34 (+0.25), CELG: 115.88 (+0.16), ZTS: 45.46 (-0.33), UA: 73.76 (-0.19), AA: 15.81 (+0.16), GILD: 101.90 (+1.10), STI: 41.57 (+0.01), GM: 37.62 (-0.40), AGIO: 118.55 (+0.11), CRL: 73.61 (-0.33), FSL: 37.53 (+2.83), VIAB: 68.98 (+1.27), CL: 70.08 (+0.23)
Charles River Laboratories International's (CRL) CEO James Foster on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Feb 11, 3:17PM CST
CRL: 73.61 (-0.33)
Charles River Laboratories to Present at Leerink Global Healthcare Conference
Business Wire - Wed Feb 11, 3:15PM CST
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Leerink Global Healthcare Conference in New York on Thursday, February 12th, at 10:20 a.m. EST. Management will present an overview of Charles River's strategic focus and business developments.
CRL: 73.61 (-0.33)
Shares of CRL Up 18.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Feb 11, 11:17AM CST
SmarTrend identified an Uptrend for Charles River Laboratories (NYSE:CRL) on October 17th, 2014 at $61.11. In approximately 4 months, Charles River Laboratories has returned 18.85% as of today's recent price of $72.63.
CRL: 73.61 (-0.33)
Charles River Laboratories ups earnings 42% in Q4
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 9:41AM CST
CRL: 73.61 (-0.33)
Charles River (CRL) Beats on Q4 Earnings and Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 8:54AM CST
Charles River Laboratories (CRL) reported fourth-quarter 2014 earnings (excluding special items) of 81 cents per share, easily beating both the Zacks Consensus Estimate of 71 cents.
BIIB: 391.66 (-0.45), ABC: 100.34 (+0.51), MCK: 224.89 (+0.12), CRL: 73.61 (-0.33)
Charles River Laboratories beats by $0.09, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 3:35PM CST
CRL: 73.61 (-0.33)
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2014 Results from Continuing Operations and Provides 2015 Guidance
Business Wire - Tue Feb 10, 3:30PM CST
--- Fourth-Quarter GAAP Earnings per Share of $0.59 and Non-GAAP Earnings per Share of $0.81 -
CRL: 73.61 (-0.33)
Notable earnings after Tuesday’s close
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 4:35PM CST
SGMO: 15.40 (+0.14), USNA: 101.37 (+0.53), RLOC: 3.58 (+0.42), ATEN: 4.14 (-0.09), VSAT: 62.71 (+0.53), RPXC: 13.94 (+0.42), TRMB: 26.86 (-0.40), KGC: 2.81 (-0.17), WSH: 47.83 (-0.55), TSRA: 39.27 (-0.05), FTI: 41.05 (+1.26), ACGL: 59.95 (+0.36), LOCK: 14.10 (-0.19), CERN: 70.98 (+1.15), CAP: 24.72 (-0.61), JIVE: 5.34 (+0.02), WU: 19.02 (+0.71), AKAM: 68.77 (+1.18), SKT: 36.80 (-0.21), NCR: 28.71 (+0.21), FRT: 143.96 (-0.58), SCI: 24.76 (+0.02), ELON: 1.16 (-0.01), GNW: 8.67 (+0.17), RKUS: 10.53 (-0.12), GHDX: 31.12 (+0.28), BLKB: 44.45 (+0.50), PXD: 157.85 (+9.71), SGEN: 31.57 (+0.36), OHI: 40.61 (-0.06), THOR: 40.01 (+0.54), MKTO: 28.24 (+0.20), CRL: 73.61 (-0.33), TMH: 59.69 (-0.19), ANDE: 45.11 (+0.71), XOOM: 15.77 (+0.64), HIW: 46.66 (-0.68), PAYC: 32.37 (-0.71)
Carl Subsidiary Hires Chief Technology Officer
Marketwired - Thu Feb 05, 8:03AM CST
Carl Capital Corp. ("Carl" or the "Corporation"
(CSE: CRL), a developer of proprietary software as a service ("SaaS" -based solutions for data integration and business intelligence, is pleased to announce that Carl's wholly owned subsidiary, Extend to Social Media Inc. ("ETS" , has appointed Piotr Stepinski ("Piotr" as its Chief Technology Officer. Piotr is an accomplished systems engineer with interests in Microsoft BI stack and Sharepoint. His academic background includes a Master of Science degree in Electronics, Telecommunications and Informatics where he concentrated in GIS Systems and Knowledge Engineering. After an extensive career as a systems engineer for several companies, including Aetna, Telzas, Scandisoft and Infotech, Piotr began consulting with companies in countries around the world.
CRL: 73.61 (-0.33)
Charles River Laboratories Shares Up 14.4% Since SmarTrend's Buy Recommendation (CRL)
Comtex SmarTrend(R) - Tue Jan 27, 9:11AM CST
SmarTrend identified an Uptrend for Charles River Laboratories (NYSE:CRL) on October 17th, 2014 at $61.11. In approximately 3 months, Charles River Laboratories has returned 14.38% as of today's recent price of $69.90.
CRL: 73.61 (-0.33)
Charles River reports February 10
Seeking Alpha - at Seeking Alpha - Mon Jan 26, 3:44PM CST
CRL: 73.61 (-0.33)
Charles River Laboratories Schedules Fourth-Quarter 2014 Earnings and 2015 Guidance Release and Conference Call
Business Wire - Mon Jan 26, 3:15PM CST
Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2014 financial results and provide 2015 guidance on Tuesday, February 10th, after the market closes. A conference call has been scheduled to discuss this information on Wednesday, February 11th, at 9:00 a.m. ET.
CRL: 73.61 (-0.33)
Jim Cramer's Top Stock Picks: MNST ESPR CRL
at The Street - Thu Jan 15, 5:00AM CST
Cramer says there's a lot to like about Monster Beverage and Esperion Therapeutics has some exciting cholesterol treatments under development.
MNST: 117.74 (-1.77), ESPR: 67.13 (-0.33), CRL: 73.61 (-0.33)
Cramer's Mad Money: Dogs And Cats (1/14/15)
SA Editor Michael Hopkins - at Seeking Alpha - Thu Jan 15, 12:05AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday, January 14. Need to figure out the market? Look no further than the household pet. In his show Wednesday, Cramer said the unpredictable market action...
NFLX: 466.10 (+9.37), KO: 41.99 (-0.18), MNST: 117.74 (-1.77), ESPR: 67.13 (-0.33), CAT: 85.13 (+1.60), CRL: 73.61 (-0.33), OAS: 16.84 (-0.03)
Jim Cramer's 'Mad Money' Recap: Will You Still Hate the Markets Tomorrow?
at The Street - Wed Jan 14, 7:22PM CST
Cramer wonders how the markets that were so loved just a few weeks ago could be so hated this week.
KO: 41.99 (-0.18), CY: 14.76 (+0.01), MNST: 117.74 (-1.77), TK: 46.69 (+1.36), NXPI: 84.79 (-0.60), ADBE: 76.51 (+1.92), VEEV: 30.12 (+0.17), SBUX: 91.58 (-0.24), ESPR: 67.13 (-0.33), TSO: 81.92 (+0.50), PZZA: 62.11 (-1.11), NAT: 10.20 (+0.10), DPZ: 100.00 (-0.56), SYRG: 11.87 (-0.12), CRL: 73.61 (-0.33), STM: 8.91 (-0.21)
Charles River Laboratories to Present at J.P. Morgan Healthcare Conference
Business Wire - Mon Jan 12, 7:00AM CST
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the J.P. Morgan 33rd Annual Healthcare Conference in San Francisco, California on Wednesday, January 14th, at 9:30 a.m. PST (12:30 p.m. EST), followed by a question and answer session at 10:00 a.m. PST (1:00 p.m. EST). Management will present an overview of Charles River's strategic focus and business developments.
JPM: 59.67 (+0.10), CRL: 73.61 (-0.33)
Express Scripts (ESRX) Picks AbbVie's Hepatitis C Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 3:50PM CST
Pharmacy benefit manager Express Scripts (ESRX) announced an update to its National Preferred Formulary, which will now include AbbVie's (ABBV) recently approved new medication for hepatitis C, Viekira Pak.
JNJ: 99.62 (+1.18), ESRX: 84.90 (+0.40), GILD: 101.90 (+1.10), ABBV: 58.05 (+1.00), CRL: 73.61 (-0.33)
Jim Cramer's 'Mad Money' Recap: Get Ready to Profit on Europe-Induced Weakness
at The Street - Wed Feb 11, 7:14PM CST
Lots of investors are worried about Europe, Cramer says, but you don't have to be.
KMI: 41.97 (+0.21), ACHC: 63.20 (-0.45), FLEX: 12.05 (-0.09), GE: 25.15 (+0.26), BBT: 38.28 (-0.04), AWAY: 29.68 (+0.11), XOM: 93.37 (+1.00), KEY: 14.11 (-0.08), INTC: 34.36 (+0.23), AFFX: 11.45 (+0.02), TWX: 83.87 (+0.56), PEP: 99.13 (-1.14), AEP: 57.83 (-0.15), ETP: 60.17 (+0.96), CMG: 674.89 (+4.60), QLYS: 47.95 (+1.46), GOOGL: 551.16 (+5.15), MSFT: 43.87 (+0.78), HSIC: 143.18 (+0.72), AAPL: 127.08 (+0.62), REGN: 402.40 (+0.66), CSCO: 29.43 (-0.03), CY: 14.76 (+0.01), SWKS: 81.85 (-0.57), PWR: 28.76 (-0.10), FB: 75.74 (-0.49), PFE: 34.64 (-0.23), HAL: 44.19 (+1.42), AMGN: 153.48 (+0.30), BAC: 16.61 (-0.06), BMY: 60.04 (+0.56), BA: 149.73 (+1.64), HPQ: 38.56 (+0.19), RAD: 8.34 (+0.25), CELG: 115.88 (+0.16), ZTS: 45.46 (-0.33), UA: 73.76 (-0.19), AA: 15.81 (+0.16), GILD: 101.90 (+1.10), STI: 41.57 (+0.01), GM: 37.62 (-0.40), AGIO: 118.55 (+0.11), CRL: 73.61 (-0.33), FSL: 37.53 (+2.83), VIAB: 68.98 (+1.27), CL: 70.08 (+0.23)
Charles River Laboratories International's (CRL) CEO James Foster on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Feb 11, 3:17PM CST
CRL: 73.61 (-0.33)
Charles River Laboratories to Present at Leerink Global Healthcare Conference
Business Wire - Wed Feb 11, 3:15PM CST
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Leerink Global Healthcare Conference in New York on Thursday, February 12th, at 10:20 a.m. EST. Management will present an overview of Charles River's strategic focus and business developments.
CRL: 73.61 (-0.33)
Shares of CRL Up 18.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Feb 11, 11:17AM CST
SmarTrend identified an Uptrend for Charles River Laboratories (NYSE:CRL) on October 17th, 2014 at $61.11. In approximately 4 months, Charles River Laboratories has returned 18.85% as of today's recent price of $72.63.
CRL: 73.61 (-0.33)
Charles River Laboratories ups earnings 42% in Q4
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 9:41AM CST
CRL: 73.61 (-0.33)
Charles River (CRL) Beats on Q4 Earnings and Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 8:54AM CST
Charles River Laboratories (CRL) reported fourth-quarter 2014 earnings (excluding special items) of 81 cents per share, easily beating both the Zacks Consensus Estimate of 71 cents.
BIIB: 391.66 (-0.45), ABC: 100.34 (+0.51), MCK: 224.89 (+0.12), CRL: 73.61 (-0.33)
Charles River Laboratories beats by $0.09, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 3:35PM CST
CRL: 73.61 (-0.33)
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2014 Results from Continuing Operations and Provides 2015 Guidance
Business Wire - Tue Feb 10, 3:30PM CST
--- Fourth-Quarter GAAP Earnings per Share of $0.59 and Non-GAAP Earnings per Share of $0.81 -
CRL: 73.61 (-0.33)
Notable earnings after Tuesday’s close
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 4:35PM CST
SGMO: 15.40 (+0.14), USNA: 101.37 (+0.53), RLOC: 3.58 (+0.42), ATEN: 4.14 (-0.09), VSAT: 62.71 (+0.53), RPXC: 13.94 (+0.42), TRMB: 26.86 (-0.40), KGC: 2.81 (-0.17), WSH: 47.83 (-0.55), TSRA: 39.27 (-0.05), FTI: 41.05 (+1.26), ACGL: 59.95 (+0.36), LOCK: 14.10 (-0.19), CERN: 70.98 (+1.15), CAP: 24.72 (-0.61), JIVE: 5.34 (+0.02), WU: 19.02 (+0.71), AKAM: 68.77 (+1.18), SKT: 36.80 (-0.21), NCR: 28.71 (+0.21), FRT: 143.96 (-0.58), SCI: 24.76 (+0.02), ELON: 1.16 (-0.01), GNW: 8.67 (+0.17), RKUS: 10.53 (-0.12), GHDX: 31.12 (+0.28), BLKB: 44.45 (+0.50), PXD: 157.85 (+9.71), SGEN: 31.57 (+0.36), OHI: 40.61 (-0.06), THOR: 40.01 (+0.54), MKTO: 28.24 (+0.20), CRL: 73.61 (-0.33), TMH: 59.69 (-0.19), ANDE: 45.11 (+0.71), XOOM: 15.77 (+0.64), HIW: 46.66 (-0.68), PAYC: 32.37 (-0.71)
Carl Subsidiary Hires Chief Technology Officer
Marketwired - Thu Feb 05, 8:03AM CST
Carl Capital Corp. ("Carl" or the "Corporation"
(CSE: CRL), a developer of proprietary software as a service ("SaaS" -based solutions for data integration and business intelligence, is pleased to announce that Carl's wholly owned subsidiary, Extend to Social Media Inc. ("ETS" , has appointed Piotr Stepinski ("Piotr" as its Chief Technology Officer. Piotr is an accomplished systems engineer with interests in Microsoft BI stack and Sharepoint. His academic background includes a Master of Science degree in Electronics, Telecommunications and Informatics where he concentrated in GIS Systems and Knowledge Engineering. After an extensive career as a systems engineer for several companies, including Aetna, Telzas, Scandisoft and Infotech, Piotr began consulting with companies in countries around the world. CRL: 73.61 (-0.33)
Charles River Laboratories Shares Up 14.4% Since SmarTrend's Buy Recommendation (CRL)
Comtex SmarTrend(R) - Tue Jan 27, 9:11AM CST
SmarTrend identified an Uptrend for Charles River Laboratories (NYSE:CRL) on October 17th, 2014 at $61.11. In approximately 3 months, Charles River Laboratories has returned 14.38% as of today's recent price of $69.90.
CRL: 73.61 (-0.33)
Charles River reports February 10
Seeking Alpha - at Seeking Alpha - Mon Jan 26, 3:44PM CST
CRL: 73.61 (-0.33)
Charles River Laboratories Schedules Fourth-Quarter 2014 Earnings and 2015 Guidance Release and Conference Call
Business Wire - Mon Jan 26, 3:15PM CST
Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2014 financial results and provide 2015 guidance on Tuesday, February 10th, after the market closes. A conference call has been scheduled to discuss this information on Wednesday, February 11th, at 9:00 a.m. ET.
CRL: 73.61 (-0.33)
Jim Cramer's Top Stock Picks: MNST ESPR CRL
at The Street - Thu Jan 15, 5:00AM CST
Cramer says there's a lot to like about Monster Beverage and Esperion Therapeutics has some exciting cholesterol treatments under development.
MNST: 117.74 (-1.77), ESPR: 67.13 (-0.33), CRL: 73.61 (-0.33)
Cramer's Mad Money: Dogs And Cats (1/14/15)
SA Editor Michael Hopkins - at Seeking Alpha - Thu Jan 15, 12:05AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday, January 14. Need to figure out the market? Look no further than the household pet. In his show Wednesday, Cramer said the unpredictable market action...
NFLX: 466.10 (+9.37), KO: 41.99 (-0.18), MNST: 117.74 (-1.77), ESPR: 67.13 (-0.33), CAT: 85.13 (+1.60), CRL: 73.61 (-0.33), OAS: 16.84 (-0.03)
Jim Cramer's 'Mad Money' Recap: Will You Still Hate the Markets Tomorrow?
at The Street - Wed Jan 14, 7:22PM CST
Cramer wonders how the markets that were so loved just a few weeks ago could be so hated this week.
KO: 41.99 (-0.18), CY: 14.76 (+0.01), MNST: 117.74 (-1.77), TK: 46.69 (+1.36), NXPI: 84.79 (-0.60), ADBE: 76.51 (+1.92), VEEV: 30.12 (+0.17), SBUX: 91.58 (-0.24), ESPR: 67.13 (-0.33), TSO: 81.92 (+0.50), PZZA: 62.11 (-1.11), NAT: 10.20 (+0.10), DPZ: 100.00 (-0.56), SYRG: 11.87 (-0.12), CRL: 73.61 (-0.33), STM: 8.91 (-0.21)
Charles River Laboratories to Present at J.P. Morgan Healthcare Conference
Business Wire - Mon Jan 12, 7:00AM CST
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the J.P. Morgan 33rd Annual Healthcare Conference in San Francisco, California on Wednesday, January 14th, at 9:30 a.m. PST (12:30 p.m. EST), followed by a question and answer session at 10:00 a.m. PST (1:00 p.m. EST). Management will present an overview of Charles River's strategic focus and business developments.
JPM: 59.67 (+0.10), CRL: 73.61 (-0.33)
Express Scripts (ESRX) Picks AbbVie's Hepatitis C Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 3:50PM CST
Pharmacy benefit manager Express Scripts (ESRX) announced an update to its National Preferred Formulary, which will now include AbbVie's (ABBV) recently approved new medication for hepatitis C, Viekira Pak.
JNJ: 99.62 (+1.18), ESRX: 84.90 (+0.40), GILD: 101.90 (+1.10), ABBV: 58.05 (+1.00), CRL: 73.61 (-0.33)
